Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Nordea in connection with Karo Intressenter’s public offer for Karo Pharma
Mandate

Vinge advised Nordea in connection with Karo Intressenter’s public offer for Karo Pharma

September 19, 2022 Capital Markets and Public M&A Life Sciences & Health

Vinge has advised Nordea Bank Abp, filial i Sverige, Corporate Finance in connection with the rendering of a fairness opinion regarding Karo Intressenter’s public offer to the shareholders of Karo Pharma AB.

Vinges team consisted through public M&A and capital markets partner Erik Sjöman.

Related

Vinge has advised Oncopeptides in connection with a directed share issue

 Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

 Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026

Vinge has advised Orexo in connection with its rights issue

 Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026